OCUGEN INC. - COMMON STOCK

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa

05 Aug 2024 05:30:33 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock

02 Aug 2024 14:22:33 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock

31 Jul 2024 20:15:46 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Proposed Public Offering of Common Stock

31 Jul 2024 15:15:04 By Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results

29 Jul 2024 06:02:15 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy

25 Jul 2024 05:30:20 By Nasdaq GlobeNewswire

Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

21 Jun 2024 06:00:00 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication

20 Jun 2024 05:30:31 By Nasdaq GlobeNewswire

Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy

31 May 2024 07:36:49 By Nasdaq GlobeNewswire

Ocugen to Present at BIO International Convention 2024

29 May 2024 06:15:00 By Nasdaq GlobeNewswire

Ocugen Set to Join Russell 3000® Index Effective June 28, 2024

28 May 2024 06:02:39 By Nasdaq GlobeNewswire

Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024

20 May 2024 06:00:52 By Nasdaq GlobeNewswire

Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

15 May 2024 05:30:00 By Nasdaq GlobeNewswire

Ocugen Provides Business Update with First Quarter 2024 Financial Results

14 May 2024 07:00:25 By Nasdaq GlobeNewswire

Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

10 May 2024 15:05:06 By Nasdaq GlobeNewswire

Ocugen to Present at May 2024 Investor Conferences

10 May 2024 06:45:07 By Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results

03 May 2024 06:30:05 By Nasdaq GlobeNewswire

Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress

02 May 2024 06:15:46 By Nasdaq GlobeNewswire

Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024

29 Apr 2024 05:45:00 By Nasdaq GlobeNewswire

UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

26 Apr 2024 08:05:24 By Nasdaq GlobeNewswire